Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bivalent RQ3027 and RQ3025 mRNA Vaccine Boosters
NCT05907044Completed
- Sponsor
- Second People's Hospital of Yunnan Province
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Vaccine mRNA, mRNA Vaccines, Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of RQ3027 and RQ3025 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Second People's Hospital of Yunnan Province. Primary endpoints: Geometric Mean Titer of SARS-CoV-2 Antibodies at Day 14 and Number of Participants with Solicited Local and Systemic Adverse Events at Day 14. Started May 2023; status: completed.
02
Drugs
RQ3027RQ3025
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05907044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907044.